DeepMed Research

Resiquimod

Generic Name: Resiquimod

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₂₂N_₄O_₂

CAS Number: 144875-48-9

Unique Ingredient Identifier: V3DMU7PVXF

Background: A substance being studied in the treatment of some types of skin cancer. When put on the skin, resiquimod causes some immune cells to make certain chemicals that may help them kill tumor cells. It is also being studied to find out if adding it to a tumor vaccine improves the antitumor immune response. It is a type of imidazoquinoline and a type of immunomodulator.

Indication: Investigated for use/treatment in genital herpes.

Clinical Trials

Lung Immune Challenge Study: Controlled Exposure to Inhaled Resiquimod (R848)

Not Applicable

Recruiting

Conditions: Mucosal Immunity
Asthma
Viral Infection
Innate Immunity

Interventions: Drug: R848
Drug: Saline

First Posted Date: 2024-07-05

Last Posted Date: 2024-07-10

Lead Sponsor: Akhilesh Jha

Target Recruit Count: 36

Registration Number: NCT06488118

Locations: 🇬🇧
NIHR Cambridge Clinical Research Facility, Cambridge, Cambridgeshire, United Kingdom

Nasal Immune Challenge Study

Not Applicable

Recruiting

Conditions: Innate Inflammatory Response
Asthma
Nasal Allergy

Interventions: Drug: R848
Drug: Saline

First Posted Date: 2023-09-01

Last Posted Date: 2023-09-01

Lead Sponsor: Cambridge University Hospitals NHS Foundation Trust

Target Recruit Count: 24

Registration Number: NCT06021002

Locations: 🇬🇧
Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom

A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

Phase 1

Recruiting

Conditions: Non-muscle-invasive Bladder Cancer

Interventions: Drug: STM-416

First Posted Date: 2023-02-02

Last Posted Date: 2024-12-06

Lead Sponsor: SURGE Therapeutics

Target Recruit Count: 75

Registration Number: NCT05710848

Locations: 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
Houston Methodist, Houston, Texas, United States
🇺🇸
The Ohio State University, Columbus, Ohio, United States

and more 7 locations

Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery

Early Phase 1

Completed

Conditions: Recurrent Melanoma
Stage IIA Melanoma
Stage IIB Melanoma
Stage IIC Melanoma
Stage IIIA Melanoma
Stage IIIB Melanoma
Stage IIIC Melanoma
Stage IV Melanoma

Interventions: Drug: Montanide ISA 51 VG
Biological: MART-1 antigen
Other: laboratory biomarker analysis
Drug: resiquimod

First Posted Date: 2012-12-12

Last Posted Date: 2018-10-09

Lead Sponsor: Mayo Clinic

Target Recruit Count: 30

Registration Number: NCT01748747

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Enhancing Influenza Vaccination in Seniors With TLR (Toll Like Receptor) Agonists

Phase 1

Completed

Conditions: Influenza Vaccination in Seniors

Interventions: Drug: resiquimod
Drug: placebo gel

First Posted Date: 2012-11-29

Last Posted Date: 2013-08-28

Lead Sponsor: University of British Columbia

Target Recruit Count: 59

Registration Number: NCT01737580

Locations: 🇨🇦
University of British Columbia Vancouver General Hospital, Vancouver, British Columbia, Canada

Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)

Phase 1

Completed

Conditions: Cutaneous T Cell Lymphoma

Interventions: Drug: Topical resiquimod 0.06%
Drug: topical resiquimod 0.03%

First Posted Date: 2012-08-31

Last Posted Date: 2019-08-13

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 13

Registration Number: NCT01676831

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Dose-finding, Safety, Efficacy Trial of Topical Resiquimod in Patients With Multiple Actinic Keratosis Lesions

Phase 2

Completed

Conditions: Actinic Keratosis

Interventions: Drug: Resiquimod 0.03%
Drug: Resiquimod 0.01%
Drug: placebo

First Posted Date: 2012-04-24

Last Posted Date: 2015-12-15

Lead Sponsor: Spirig Pharma Ltd.

Target Recruit Count: 218

Registration Number: NCT01583816

Locations: 🇩🇪
KLINIKUM VEST GmbH Knappschaftskrankenhaus, Recklinghausen, Germany
🇩🇪
Johannes Wesling Klinikum Minden, Minden, Germany
🇨🇭
Kantonsspital Aarau, Aarau, Switzerland

and more 7 locations

Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery

Early Phase 1

Completed

Conditions: Melanoma (Skin)

Interventions: Drug: resiquimod

First Posted Date: 2007-05-07

Last Posted Date: 2014-10-31

Lead Sponsor: Mayo Clinic

Target Recruit Count: 30

Registration Number: NCT00470379

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Study With a Topical Gel to Treat Common Warts in Adults

Phase 2

Completed

Conditions: Warts

First Posted Date: 2005-07-11

Last Posted Date: 2007-02-19

Lead Sponsor: Graceway Pharmaceuticals, LLC

Target Recruit Count: 88

Registration Number: NCT00117923

Locations: 🇺🇸
Oregon Medical Research Center, Portland, Oregon, United States

Study With a Topical Gel to Treat Common Warts in Adults

Phase 2

Completed

Conditions: Warts

First Posted Date: 2005-07-11

Last Posted Date: 2007-02-19

Lead Sponsor: Graceway Pharmaceuticals, LLC

Target Recruit Count: 48

Registration Number: NCT00117871

Locations: 🇺🇸
Minnesota Clinical Study Center, Fridley, Minnesota, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy